All In MedTech

Device Trial Radar · NCT02102256

A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients

A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients

Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Mar 2014

Primary completion

Apr 6, 2021

Study completion Apr 6, 2021

Sponsor

Lead sponsor
Laurie EisenbergAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Southern California; Children's Hospital Los Angeles; Huntington Medical Research Institutes
First posted
Apr 2, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
Who can join
All sexes, from 2 years, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Current treatment options for bilateral profoundly deaf children, diagnosed with inner ear anatomical abnormalities, are limited and, in the case of absent cochleas, non-existent. An auditory brainstem implant (ABI) places an electrode close to the auditory nucleus in the brainstem. Children aged 2 - 5 who are not candidates for a cochlear implant, or who did not demonstrate benefit from a cochlear implant, will be implanted with an ABI and followed for 1 year for safety and a total of 3 years for preliminary efficacy. This is a feasibility study to determine the safety of the ABI.

Conditions

  • Profound Bilateral Deafness Due to
  • Bilateral Cochlear Aplasia
  • Bilateral Cochlear Nerve Deficiency
  • Bilateral Cochlear Ossification Secondary to Meningitis

Interventions

  • Auditory Brainstem ImplantDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary EndpointTime frame: 12-months post-device (auditory brainstem implant) successful activation

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Keck School of Medicine of USC

    Los Angeles, California

  • Children's Hospital Los Angeles

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.